#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	5512	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2616	622.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1710	1710	C	764	C,T	695,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8278	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4141	598.7	0	.	n	.	0	T695C	SNP	695	695	T	1225	1225	C	645	C	568	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8278	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4141	598.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1867	1867	A	695	A	639	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8278	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4141	598.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2501	2501	C	752	C	676	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8278	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4141	598.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3127	3127	T	698	T,C,G	615,3,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8278	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4141	598.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2575	2575	A	765	A	702	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	814	folP	852	852	100.0	folP.l15.c4.ctg.1	1946	124.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1260	1262	AGC	169;168;170	A;G;C	148;148;143	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1594	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3855	123.6	1	SNP	p	S91F	0	.	.	271	273	TCC	783	785	TCC	131;131;131	T;C,A;C,A	117;120,1;123,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1594	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3855	123.6	1	SNP	p	D95N	0	.	.	283	285	GAC	795	797	GAC	132;133;132	G;A;C	124;118;120	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1594	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3855	123.6	1	SNP	p	D95G	0	.	.	283	285	GAC	795	797	GAC	132;133;132	G;A;C	124;118;120	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	772	mtrR	633	633	99.84	mtrR.l6.c17.ctg.1	2082	110.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	520	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1513	102.5	0	.	n	.	0	C187G	SNP	187	187	C	815	815	G	193	G	176	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1866	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3364	165.7	1	SNP	p	D86N	0	.	.	256	258	GAC	774	776	GAC	192;194;194	G,T;A,G,C;C	171,1;164,1,1;172	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1866	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3364	165.7	1	SNP	p	S87W	0	.	.	259	261	AGT	777	779	AGT	195;197;196	A,T;G;T	164,1;179;178	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1866	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3364	165.7	1	SNP	p	S87R	0	.	.	259	261	AGT	777	779	AGT	195;197;196	A,T;G;T	164,1;179;178	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1866	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3364	165.7	1	SNP	p	S87I	0	.	.	259	261	AGT	777	779	AGT	195;197;196	A,T;G;T	164,1;179;178	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1866	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3364	165.7	1	SNP	p	S88P	0	.	.	262	264	TCC	780	782	TCC	194;194;192	T;C;C	174;176;172	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1486	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3212	138.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1855	1857	GGC	175;174;174	G;G;C	154;153;154	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1482	1484	GCA	192;192;194	G;C;A	173;169;178	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1485	1487	ATC	194;195;198	A;T;C,A	178;177;179,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1497	1499	GTG	199;197;197	G;T;G,T	176;174;171,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1497	1499	GTG	199;197;197	G;T;G,T	176;174;171,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2001	2003	ACC	161;161;160	A;C;C	143;145;147	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2055	2057	GCG	156;156;157	G;C;G,C	131;120;124,2	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2055	2057	GCG	156;156;157	G;C;G,C	131;120;124,2	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2178	2180	GGC	154;154;155	G;G;C	124;129;129	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2187	2189	GGC	151;151;151	G;G;C,T	128;130;133,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2868	134.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2205	2207	CCG	151;152;152	C;C;G	123;133;125	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1736	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3594	144.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1846	1848	CTG	172;172;172	C,G;T;G	146,1;146;148	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1002	porA	1146	1146	99.83	porA.l6.c17.ctg.1	2394	125.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	864	864	C	159	C	149	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	G38E	NONSYN	112	114	GGA	547	549	GAA	200;199;200	G;A;A	181;171;175	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	S46G	NONSYN	136	138	AGC	571	573	GGC	203;203;203	G;G;C,G	181;181;181,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	577	579	GGA	201;199;199	G;G;A	179;173;173	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	T87A	NONSYN	259	261	ACT	694	696	GCT	200;201;200	G;C;T,G	178;180;176,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	700	702	AGC	202;201;201	A,G;G;C	174,1;182;182	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	792	793	CG	190;189	C;G,T	169;169,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	795	797	CAG	189;191;192	C,T;A;G,A	169,1;170;172,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	799	801	AAA	192;194;193	A;A;A	171;174;168	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	862	864	GAA	187;188;188	G;A;A	169;165;169	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	886	888	GCA	185;184;184	G,A;C;A,T,G	168,1;160;162,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	994	996	CGA	183;185;183	C;G;A	173;174;172	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1078	1080	ACT	184;183;183	A,C;C,A;T	168,2;168,1;159	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1081	1083	CAT	184;183;183	C;A,G;T,G	171;167,1;165,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1087	1089	ATG	182;180;179	A;T;G,T,A	169;165;161,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	.	MULTIPLE	766	767	AC	1201	1203	GCA	171;171;171	G;C;A	157;156;158	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1205	1207	CGG	170;170;170	C;G;G	155;154;154	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1208	1208	A	168	A	153	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	1	SNP	p	G120K	1	.	.	358	360	AAG	792	794	CGG	190;189;189	C;G,T;G	169;169,1;173	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	1	SNP	p	D121N	0	.	.	361	363	GAC	795	798	CGC	189;192;192	C,T;G,A;C	169,1;172,1;173	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1034	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1762	168.8	1	SNP	p	A121D	1	.	.	361	363	GAC	795	798	CGC	189;192;192	C,T;G,A;C	169,1;172,1;173	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3292	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5503	179.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2334	2336	AAT	193;193;193	A,C;A;T	177,1;174;175	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	576	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1381	123.5	1	SNP	p	V57M	1	.	.	169	171	ATG	664	666	ATG	211;211;211	A;T;G	194;196;194	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
